Literature DB >> 2858182

Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate.

D E Bax, R S Amos.   

Abstract

The place of sulphasalazine in the management of rheumatoid arthritis over prolonged periods of time has been compared and contrasted with that of sodium aurothiomalate. One hundred and forty-three patients (59 on sulphasalazine, 84 on sodium aurothiomalate) have been treated for periods of up to 42 months. Sulphasalazine is highly effective for some patients, though probably less frequently than sodium aurothiomalate. However, its safety profile is far superior, and very long-term treatment with sulphasalazine is a safe option for treatment of rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2858182      PMCID： PMC1001604          DOI： 10.1136/ard.44.3.194

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  8 in total

1.  COURSE AND PROGNOSIS IN RHEUMATOID ARTHRITIS. A FURTHER REPORT.

Authors:  J J DUTHIE; P E BROWN; L H TRUELOVE; F D BARAGAR; A J LAWRIE
Journal:  Ann Rheum Dis       Date:  1964-05       Impact factor: 19.103

2.  Salazopyrin in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; E P Butler; R A Crockson; A P Crockson; L Walsh
Journal:  Agents Actions       Date:  1978-06

3.  Benefits of hospitalization in rheumatoid arthritis.

Authors:  P Lee; A C Kennedy; J Anderson; W W Buchanan
Journal:  Q J Med       Date:  1974-04

4.  A biochemical assessment of sulphasalazine in rheumatoid arthritis.

Authors:  H A Bird; J S Dixon; M E Pickup; V M Rhind; J R Lowe; M R Lee; V Wright
Journal:  J Rheumatol       Date:  1982 Jan-Feb       Impact factor: 4.666

5.  Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

Authors:  V C Neumann; K A Grindulis; S Hubball; B McConkey; V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

6.  Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

7.  Sulphasalazine in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; S Durham; P J Forster; S Hubball; L Walsh
Journal:  Br Med J       Date:  1980-02-16

8.  Preliminary criteria for clinical remission in rheumatoid arthritis.

Authors:  R S Pinals; A T Masi; R A Larsen
Journal:  Arthritis Rheum       Date:  1981-10
  8 in total
  44 in total

Review 1.  Is there a role for antibiotics in the treatment of patients with rheumatoid arthritis?

Authors:  J R O'Dell
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

2.  Enumeration of IgA producing cells by the enzyme linked immunospot (ELISPOT) technique to evaluate sulphasalazine effects in inflammatory arthritides.

Authors:  N Feltelius; S Gudmundsson; L Wennersten; O Sjöberg; R Hällgren; L Klareskog
Journal:  Ann Rheum Dis       Date:  1991-06       Impact factor: 19.103

3.  Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies.

Authors:  L Altomonte; A Zoli; A Veneziani; L Mirone; G Santacesaria; C Chiarelli; F Federico; G Massi; M Magaro
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

4.  Treatment of psoriatic arthritis with sulphasalazine: a one year open study.

Authors:  M Farr; G D Kitas; L Waterhouse; R Jubb; D Felix-Davies; P A Bacon
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

5.  Raised serum alkaline phosphatase and aspartate transaminase levels in two rheumatoid patients treated with sulphasalazine.

Authors:  M Farr; D P Symmons; P A Bacon
Journal:  Ann Rheum Dis       Date:  1985-11       Impact factor: 19.103

6.  Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash.

Authors:  D E Bax; R S Amos
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

7.  Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis.

Authors:  H Mielants; E M Veys; R Joos
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

Review 8.  New perspectives of secondary and tertiary therapy for rheumatoid arthritis.

Authors:  R F Willkens
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

9.  Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine.

Authors:  V A Danis; G M Franic; D A Rathjen; R M Laurent; P M Brooks
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

10.  Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis.

Authors:  D Porter; R Madhok; J A Hunter; H A Capell
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.